Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Pharmaceutical use of isolarisiresinol

A technology of isolarix and resinol, applied in the field of medicinal use of isolarix resinol

Inactive Publication Date: 2006-11-29
HEILONGJIANG TIANYI PHARMA
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Anti-endotoxin treatment for endotoxemia and induced multiple organ failure is a major topic and the most active field of research by scholars at home and abroad, but so far no drug has been officially marketed

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical use of isolarisiresinol

Examples

Experimental program
Comparison scheme
Effect test

experiment example 1

[0019] Experimental Example 1: The present invention confirms that Radix Radix isatidis has the effective part of anti-endotoxemia effect through animal experiments

[0020] Test drug solution: the extracts obtained by the above extraction processes are diluted with water to prepare a drug solution containing 2 grams of crude drug per milliliter.

[0021] Test endotoxin: use the O 111 B 4 Escherichia coli, the endotoxin was prepared and purified by our laboratory, and the O 111 B 4 Escherichia coli endotoxin was used for titer calibration. The dosage range for the preparation of endotoxemia model mice is 15-18 mg per kg body weight.

[0022] Experimental animals: purchased from the Animal Breeding Farm of the Chinese Academy of Medical Sciences, Kunming species, secondary mice. Weight range: 18-22 grams, half male and half male. Randomly divided into groups according to body weight, with no less than 30 animals in each group. The t-test was carried out for the weight of...

experiment example 2

[0030] Experimental Example 2: Separation of active ingredient monomer compounds in the effective parts of the present invention: the effective extraction parts proved by animal experiments in the above table 1 have 3 main absorption peaks in high performance liquid chromatography, and 3 main absorption peaks in thin layer chromatography. A major spot is closely related to the curative effect. Since the content of the three main components in the ethyl acetate extraction part is relatively high, the ethyl acetate extraction part is subjected to column chromatography separation.

[0031] Materials: Silica gel for column chromatography, G plate and GF254 plate for thin layer chromatography produced by Qingdao Ocean Chemical Factory. Analytical reagents such as chloroform, methanol, petroleum ether, ethyl acetate, etc. from Beijing Yili Chemical Company. Development system: petroleum ether-chloroform-methanol=4:4:1, 2:4:1, chloroform-methanol=80:1, 40:1, 20:1.

[0032] Spectrum...

experiment example 3

[0034] Experimental example 3: the action intensity and ratio of each main component in the effective part of the present invention

[0035] Preparation of the test solution: the ethyl acetate extract is separated by silica gel column chromatography, the solvent is recovered from the eluted part of chloroform and the eluted part of chloroform: methanol = 10: 1, and water is added to form a solution with a concentration of 2 g / ml of crude drug. Background solution, 5-hydroxymethylfurfural, isolaricinol ester, and 1-N-methoxy-2-oxo-indole-3-acetamide obtained by elution with different ratios of chloroform-methanol were added in different weight ratios In the background solution, select the best ratio. In order to ensure the stability of the active ingredients, the background solution of No. 3 effective part was adjusted to pH=2.5 with 5% hydrochloric acid, and the background solution of No. 6 effective part was adjusted to pH=4.5 with 5% sodium hydroxide. Experimental animals, a...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Disclosed is the pharmaceutical use of isolarisiresinol in preparing medicament for treating intestinal endotoxemia and lowering mortality caused by multiple-organ prostration induced thereby, The invention also discloses the its use in preparing medicament for treating intestinal endotoxemia caused by serious wounds, burns, war wounds, infection, major operation, heavy shock, radiotheraphy, chemotherapy, or organ transplantation stress condition, or intestinal endotoxemia as the complication of serious hepatitis, cirrhosis, gastrointestinal tract diseases, undernourishment, biliary tract intestinal obstruction, or intestinal endotoxemia induced pyaemia, purulent shock, multiple-organ dysfunction or prostration, and the use in preparing medicament for treating septicemia, acute pneumonia, acute liver prostration, acute DIC, prostration syndrome of serious shocks, and diseases caused by cytomegalovirus, herpesvirus, and influenza virus.

Description

technical field [0001] The present invention relates to the medicinal use of a compound, in particular to the medicinal use of isolaricine resinol. The patent application of the present invention is a divisional application, the original application number is 031020658, the application date is January 30, 2003, and the title of the invention is a plant extract and compound for treating endotoxemia, its extraction method and application. Background technique [0002] Endotoxin ET is the lipopolysaccharide (Lopipolysaccharide LPS) component of the cell wall of Gram-negative bacilli, and is a key pathogenic factor that mediates abnormal immune and inflammatory responses in the body. Endotoxemia is caused by the excessive entry of endogenous and exogenous endotoxins into the blood circulation, stimulating the body's immune cells to release a large number of cytokines, disrupting the balance of the body's inflammatory response, causing microcirculation disturbance and severe tiss...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/80A61P7/00A61P1/16A61P31/22A61P31/16A61P17/02A61P43/00C07D209/34
Inventor 普文英
Owner HEILONGJIANG TIANYI PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com